BR112017028121A2 - métodos para modular moléculas de vigilância de dna citosólico - Google Patents

métodos para modular moléculas de vigilância de dna citosólico

Info

Publication number
BR112017028121A2
BR112017028121A2 BR112017028121A BR112017028121A BR112017028121A2 BR 112017028121 A2 BR112017028121 A2 BR 112017028121A2 BR 112017028121 A BR112017028121 A BR 112017028121A BR 112017028121 A BR112017028121 A BR 112017028121A BR 112017028121 A2 BR112017028121 A2 BR 112017028121A2
Authority
BR
Brazil
Prior art keywords
methods
molecules
cytosolic dna
dna surveillance
surveillance molecules
Prior art date
Application number
BR112017028121A
Other languages
English (en)
Portuguese (pt)
Inventor
Abraham Albert
Weiss Christian
Keil Daniel
Nickell Jason
Ilg Thomas
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BR112017028121A2 publication Critical patent/BR112017028121A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017028121A 2015-06-26 2016-06-23 métodos para modular moléculas de vigilância de dna citosólico BR112017028121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
BR112017028121A2 true BR112017028121A2 (pt) 2018-09-04

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028121A BR112017028121A2 (pt) 2015-06-26 2016-06-23 métodos para modular moléculas de vigilância de dna citosólico

Country Status (22)

Country Link
US (1) US20190233825A1 (https=)
EP (1) EP3313376A2 (https=)
JP (1) JP2018518511A (https=)
KR (1) KR20180021874A (https=)
CN (1) CN108472255A (https=)
AR (1) AR105160A1 (https=)
AU (1) AU2016282879A1 (https=)
BR (1) BR112017028121A2 (https=)
CA (1) CA2990526A1 (https=)
CL (1) CL2017003373A1 (https=)
CR (1) CR20180003A (https=)
DO (1) DOP2017000313A (https=)
HK (1) HK1256128A1 (https=)
IL (1) IL256264A (https=)
MX (1) MX2017017141A (https=)
PE (1) PE20181208A1 (https=)
PH (1) PH12017502413A1 (https=)
RU (1) RU2018102915A (https=)
SG (1) SG10201913395VA (https=)
TW (1) TW201710509A (https=)
UY (1) UY36756A (https=)
WO (1) WO2016207314A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
TWI759317B (zh) 2016-07-26 2022-04-01 德商拜耳動物保健有限公司 牛物種中增加的生育力
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
TW200505425A (en) * 2003-05-29 2005-02-16 Schering Plough Ltd Compositions and method for treating infection in cattle and swine
PT2942391T (pt) * 2004-08-13 2018-10-09 Univ Pennsylvania Métodos de produção de vacinas não resistentes aos antibióticos
WO2006017857A2 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
WO2010130374A1 (en) * 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
BR112013016231B1 (pt) * 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
KR20160122849A (ko) * 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드

Also Published As

Publication number Publication date
WO2016207314A3 (en) 2017-02-09
CA2990526A1 (en) 2016-12-29
US20190233825A1 (en) 2019-08-01
CL2017003373A1 (es) 2018-06-29
RU2018102915A3 (https=) 2019-12-05
HK1256128A1 (zh) 2019-09-13
TW201710509A (zh) 2017-03-16
CN108472255A (zh) 2018-08-31
AR105160A1 (es) 2017-09-13
AU2016282879A1 (en) 2018-01-18
RU2018102915A (ru) 2019-07-29
MX2017017141A (es) 2018-03-09
UY36756A (es) 2017-01-31
IL256264A (en) 2018-02-28
DOP2017000313A (es) 2018-02-28
KR20180021874A (ko) 2018-03-05
JP2018518511A (ja) 2018-07-12
CR20180003A (es) 2018-03-20
SG10201913395VA (en) 2020-03-30
EP3313376A2 (en) 2018-05-02
PE20181208A1 (es) 2018-07-23
PH12017502413A1 (en) 2018-06-25
WO2016207314A2 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
GB2570593B (en) Methods relating to intestinal organ-on-a-chip
EP3188604A4 (en) Stevia extracts
IL249061A0 (en) Combination, composition, and method of administering the combination or composition to animals
EP3546544C0 (en) LIGHT-EMITTING DEVICE
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
TWI561111B (en) Led driving circuit and method using same
EP3333833A4 (en) TECHNOLOGY SIMULATOR
EP3111441A4 (en) Time compensation-based led system
EP3063459A4 (en) Led illumination device and method
DK3159296T3 (da) Reb til elevator og fremstillingsfremgangsmåde dertil
BR112016023752A2 (pt) utilização de lactobacillus rhamnosus para promover a recuperação da diversidade da microbiota intestinal após disbiose
FR3031163B3 (fr) Module de del montable magnetiquement
BR112017028121A2 (pt) métodos para modular moléculas de vigilância de dna citosólico
GB201704361D0 (en) LED verticle chip structure with special coarsening morphology and preparation method therefor
IL252683B (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
BR112017013868A2 (pt) dispositivo de fornecimento e processo de fornecimento de elementos
EP3259921A4 (en) Identifying content appropriate for children algorithmically without human intervention
IL250699A0 (en) Medical procedure simulator
IL248877B (en) Compositions and methods for enhancing immunity
DK3325501T3 (da) Anti-tumor immunresponser til modificerede selv-epitoper
EP3172763A4 (en) Design and methods to package and interconnect high intensity led devices
HRP20181112T1 (hr) Supstituirani derivati azaspiro(4,5)dekana
PL3340321T3 (pl) Proces pakowania wiązanego diod led za pomocą odkształcalnego fotokonwertera organicznej żywicy silikonowej
EP3321980A4 (en) Equipment system using deformable organic silicone resin photoconverter to bond-package led
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2728 DE 18/04/2023.